Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Akoya BioSciences, Inc. (AKYA)
Company Research
Source: GlobeNewswire
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust Akoya’s platforms will be used for deep spatial proteomic profiling of thousands of tissue samples from cancer patients to identify biomarkers predicting treatment success MARLBOROUGH, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that the company’s PhenoCycler® Fusion and PhenoImager® HT spatial proteomics platforms will be used to analyze tissue samples as part of the MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity) program. This multimillion-dollar initiative, funded by the UK Office of Life Sciences (OLS) and the Medical Research Council (MRC), aims to advance cancer immunotherapy research through deep multi-omic profiling. The MANIFEST consortium brings together leading cancer researchers, academic in
Show less
Read more
Impact Snapshot
Event Time:
AKYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKYA alerts
High impacting Akoya BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
AKYA
News
- Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024GlobeNewswire
- Akoya Biosciences Announces Scott Mendel as Chairman of the Board of DirectorsGlobeNewswire
- Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.00. They now have an "overweight" rating on the stock.MarketBeat
- Akoya Biosciences Second Quarter 2024 Earnings: Revenues Disappoint [Yahoo! Finance]Yahoo! Finance
- Akoya Biosciences, Inc. (NASDAQ: AKYA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.MarketBeat
AKYA
Earnings
- 8/5/24 - Miss
AKYA
Sec Filings
- 10/4/24 - Form 4
- 10/3/24 - Form 8-K
- 9/3/24 - Form 4
- AKYA's page on the SEC website